Centogene N.V. (Nasdaq: CNTG) (“we” or the “Company”), the
essential life science partner for data-driven answers in rare and
neurodegenerative diseases, today announced financial results for
the fiscal year ended December 31, 2023, and provided a business
update.
“In 2023, we focused on strategic growth – strengthening our
Diagnostic portfolio and introducing new data and wet lab solutions
to accelerate drug discovery, development, and commercialization
for Pharma. We expanded our partnership model with a joint venture
in Saudi Arabia, securing a $30 million investment and additional
milestone payments. However, delays in Pharma program timelines
impacted our 2023 revenue. Looking ahead to 2024, our Diagnostics
business is expected to maintain steady growth in line with
industry standards, and our Pharma orderbook is on a record
trajectory – with momentum expected to compound each quarter.”
Kim Stratton continued, “We are excited to be engaged in
discussions with multiple potential strategic partners and to have
deepened our relationship with Lifera over the past months. With
this progress at the forefront, CENTOGENE is positioned for growth
and a path towards profitability. We expect to see 2024 annual
revenue growth between 10-15%.”
Full Year
2023 Financial
Highlights
- Total revenues increased by
2% to €48.5 million in FY2023, compared to €47.5 million in
FY2022
- Diagnostics segment revenues
increased by 8% in 2023 to €33.7 million, primarily related to an
increase of 11% in revenues for CentoXome® (CENTOGENE’s proprietary
Whole Exome Sequencing) and CentoGenome® (CENTOGENE’s proprietary
Whole Genome Sequencing). Achieved upselling 47% of CentoXome® and
CentoGenome® orders to MOx (CENTOGENE’s portfolio of multiomic
testing solutions) in FY2023
- Pharma segment revenues of
€14.8 million, reflecting a decrease of 8%, primarily driven by a
lag in Pharma program timelines in H2 2023
- Overall gross profit margin of
36% of revenues or €17.2 million in FY2023, compared to 42% of
revenues or €19.8 million in FY2022
- Net loss position increased by 12.2%
at €35.8 million in FY2023 compared to a net loss of €31.9 million
in FY2022
- Total segment adjusted EBITDA was at
€11.1 million in FY2023, compared to €13.2 million in FY2022. This
decrease was mainly driven by the lag in pharma revenues, as well
as the increase in cost of sales and selling expenses
- Cash and cash equivalents
were €19.1 million as of December 31, 2023, compared to €35.9
million for the period ended December 31, 2022
“We are focused on streamlining processes and strengthening our
financial position to enable us to execute on our leading rare and
neurodegenerative disease business and sustainable long-term value
creation,” said Miguel Coego, Chief Financial Officer at CENTOGENE.
“Looking ahead, we will remain prudent with our capital allocation
– serving as a key driver to our goal of hitting EBITDA breakeven
by the end of this year and our path to cash profitability. We
believe this will enable us to advance our strategic alternatives
process to unlock value for our patients, physicians, pharma
partners, and CENTOGENE stakeholders.”
Recent Business Highlights
Corporate
- Announced strategic collaboration
with Lifera, a biopharmaceutical company wholly-owned by the PIF,
with the formation of a joint venture (JV), Lifera Omics, to
increase local and regional access and rapid delivery of
world-class genomic and multiomic testing to patients in Saudi
Arabia and countries of the Gulf Cooperation Council (GCC). Under
the terms of the collaboration, CENTOGENE received a $30 million
mandatory convertible loan from Lifera, as well as milestone
payments
- Secured an additional approximately
$20 million proceeds from Lifera via the sale of $15 million in
CENTOGENE’s accounts receivables (AR) in Saudi Arabia at face value
with no recourse. Additionally, Lifera purchased 16% of CENTOGENE’s
stake into their JV at a value of approximately $5 million with
CENTOGENE maintaining 4% ownership in the JV with the option to
repurchase the previous ownership on substantially the same terms
in the next 6-24 months. CENTOGENE to remain active in Lifera
Omics’ operations to deliver genomic and multiomic testing
- Initiated strategic alternatives
process focused on sustainable long-term value creation for the
benefit of its stakeholders
- Expanded the CENTOGENE Biodatabank
to over 850,000 patients, over 70% of whom are of non- European
descent, approximately 30,000 active physicians, and more than 85
million unique variants thanks to the increasing number of
CentoXome® and CentoGenome® analyses, which contain significantly
more variants than more targeted diagnostic tests
- Authored over 30 peer-reviewed
scientific publications in FY2023, reaching a milestone of over 300
publications in the Company’s history. The research unlocked
insights into Parkinson’s disease, Gaucher disease, Niemann-Pick
type C1 disease, hereditary angioedema, autosomal recessive spastic
paraplegia, colorectal carcinomas, renal hypouricemia, CLN6
disease, ELOVL4-related autosomal recessive neuro-ichthyosis,
CFTR-related disease, TOR1A-related disorders, as well as a range
of variants associated with epilepsy, genetic cancers, metabolic
disorders, developmental disorders, and other rare and
neurodegenerative diseases
Pharma
- Led 48 collaborations with 34
different pharmaceutical partners in FY2023. Of these 48
collaborations, 12 were with new partners. Starting off Q1 2024,
the Company has formed collaborations with eight new partners
- Extended Takeda partnership to March
2026 to continue providing access to genetic testing for patients
with lysosomal storage disorders
- Announced research project with The
Michael J. Fox Foundation to validate the genetic risk factors of
Parkinson’s disease using multiomics
- Reached initial recruitment and
genetic testing milestone in the observational EFRONT Study, being
conducted to advance the genetic understanding of frontotemporal
dementia (FTD)
- Leading, alongside Denali
Therapeutics, the ROPAD Study, the world’s largest observational
study on Parkinson’s disease genetics with over 15,000 enrolled
patients to date. Patients enrolled in ROPAD and identified with
LRRK2 genetic variations may be eligible for participation in
ongoing interventional clinical studies
Diagnostics
- Strong test requests of approximately
81,500 test requests for FY2023, representing an increase of
approximately 18% as compared to approximately 57,100 in the prior
year
- Strengthened Diagnostics Sales team
and expanded direct footprint distribution network in targeted
geographic areas, such as Canada, Colombia, Italy, Spain, and
Portugal
- Expanded MOx, the Company’s
multiomic diagnostic portfolio, now incorporating cutting-edge
transcriptomic analysis. CENTOGENE’s MOx 2.0 is a single-step
multiomic solution that combines DNA sequencing, biochemical
testing, and now RNA sequencing to provide physicians with the most
comprehensive testing capability
- Launched NEW CentoGenome®, the
world's most comprehensive Whole Genome Sequencing tool for
diagnosis of rare and neurodegenerative diseases, which now detects
Copy Number Variations associated with spinal muscular atrophy, as
well as complex disease-causing variants associated with Gaucher
disease and susceptibility to GBA1-related Parkinson's disease
- Launched CENTOGENE’s FilterTool to
fuel rapid, reliable analysis for diagnosis and research of rare
genetic diseases by significantly reducing time- and
resource-intensive processes – enabling users to display, filter,
select, and classify variants. Seamlessly integrating with
CentoCloud®, CENTOGENE’s CE-marked Software as a Service (SaaS)
bioinformatics pipeline, FilterTool is one of the first
applications to receive CE mark under new In Vitro Diagnostic
Regulation (IVDR) from the European Parliament
- Launched together with TWIST
Bioscience three Next Generation Sequencing target enrichment
panels, Twist Alliance CNTG Exome, Twist Alliance CNTG Rare Disease
Panel, and Twist Alliance CNTG Hereditary Oncology Panel, to
support rare disease and hereditary cancer research and support
diagnostics
- Integrated Illumina’s new NovaSeq X
Plus Sequencer into the Company’s state-of-the-art, CAP/CLIA
accredited laboratory in Rostock, Germany, to further optimize
throughput, scale, and cost efficiencies
- Published research in Science in
collaboration with the Laboratory of Human Genetics of Infectious
Diseases at Institut Imagine on human pre-T cell receptor alpha
(pre-TCRα) deficiency and its effect on human immunity
- Published study in the European
Journal of Human Genetics revealing unique genetic variants in
world's largest Niemann-Pick type C1 disease cohort
- Published the discovery of a new
form of early-onset dystonia and parkinsonism in the context of
neurodevelopmental abnormalities associated to the gene called
ACBD6 (Acyl-CoA Binding Domain Containing 6) as part of an
international team of researchers. The landmark study’s findings
have been published in Brain
- Published a study in the Diagnostics
journal establishing lyso-Gb1 (glucosylsphingosine) as a predictive
biomarker
2024 Revenue
Guidance
The Company expects revenue growth to be between 10-15% in
FY2024 compared to FY2023.
Update on Process to Review Strategic
Alternatives
On February 28, 2024, we announced a process to explore
strategic alternatives, including the sale of the Company,
divestitures of asset, licensing/partnership transactions, and/or
additional financing. We engaged an investment banker firm to
advise us in connection with this process. We are currently in
active discussions with several interested parties, which could
result in a near-term transaction by July 15, 2024. We do not
expect to disclose developments unless and until our board of
directors has concluded that disclosure is appropriate or required.
There can be no assurance that our strategic review process will
result in any transaction or other strategic outcome. We do not
intend to disclose further developments on this strategic review
process unless and until we determine that such disclosure is
appropriate or necessary.
About CENTOGENE
CENTOGENE’s mission is to provide data-driven, life-changing
answers to patients, physicians, and pharma companies for rare and
neurodegenerative diseases. We integrate multiomic technologies
with the CENTOGENE Biodatabank – providing dimensional analysis to
guide the next generation of precision medicine. Our unique
approach enables rapid and reliable diagnosis for patients,
supports a more precise physician understanding of disease states,
and accelerates and de-risks targeted pharma drug discovery,
development, and commercialization.
Since our founding in 2006, CENTOGENE has been offering rapid
and reliable diagnosis – building a network of approximately 30,000
active physicians. Our ISO, CAP, and CLIA certified multiomic
reference laboratories in Germany utilize Phenomic, Genomic,
Transcriptomic, Epigenomic, Proteomic, and Metabolomic datasets.
This data is captured in our CENTOGENE Biodatabank, with over
850,000 patients represented from over 120 highly diverse
countries, over 70% of whom are of non-European descent. To date,
the CENTOGENE Biodatabank has contributed to generating novel
insights for more than 300 peer-reviewed publications.
By translating our data and expertise into tangible insights, we
have supported over 50 collaborations with pharma partners.
Together, we accelerate and de-risk drug discovery, development,
and commercialization in target and drug screening, clinical
development, market access and expansion, as well as offering
CENTOGENE Biodata Licenses and Insight Reports to enable a world
healed of all rare and neurodegenerative diseases.
To discover more about our products, pipeline, and
patient-driven purpose, visit www.centogene.com and follow us on
LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the U.S. federal securities laws. Statements
contained herein that are not clearly historical in nature are
forward-looking, and the words “anticipate,” “believe,”
“continues,” “expect,” “estimate,” “intend,” “project,” “plan,” “is
designed to,” “potential,” “predict,” “objective” and similar
expressions and future or conditional verbs such as “will,”
“would,” “should,” “could,” “might,” “can,” and “may,” or the
negative of these are generally intended to identify
forward-looking statements. Such forward-looking statements involve
known and unknown risks, uncertainties, and other important factors
that may cause CENTOGENE’s actual results, performance, or
achievements to be materially different from any future results,
performance, or achievements expressed or implied by the forward-
looking statements. Such risks and uncertainties include, among
others, our ability to achieve the revenue levels set forth in our
guidance, negative economic and geopolitical conditions and
instability and volatility in the worldwide financial markets,
possible changes in current and proposed legislation, regulations
and governmental policies, pressures from increasing competition
and consolidation in our industry, the expense and uncertainty of
regulatory approval, including from the U.S. Food and Drug
Administration, our reliance on third parties and collaboration
partners, including our ability to manage growth, our ability to
execute our business plan and strategy, including to enter into new
client relationships, our ability to execute on our announced
strategic alternatives process, our dependency on the rare disease
industry, our ability to manage international expansion, our
reliance on key personnel, our reliance on intellectual property
protection, fluctuations of our operating results due to the effect
of exchange rates, our ability to streamline cash usage, our
continued ongoing compliance with covenants linked to financial
instruments, including timing requirements with respect to our
strategic alternatives process, our requirement for additional
financing, and our ability to continue as a going concern, or other
factors. For further information on the risks and uncertainties
that could cause actual results to differ from those expressed in
these forward-looking statements, as well as risks relating to
CENTOGENE’s business in general, see CENTOGENE’s risk factors set
forth in CENTOGENE’s Form 20-F filed on May 15, 2024, with the
Securities and Exchange Commission (the “SEC”) and subsequent
filings with the SEC. Any forward-looking statements contained in
this press release speak only as of the date hereof, and CENTOGENE
specifically disclaims any obligation to update any forward-looking
statement, whether as a result of new information, future events,
or otherwise.
Non-IFRS Measures
This document may contain summarized, non-audited, or non-GAAP
financial information. The information contained herein should
therefore be considered as a whole and in conjunction with all the
public information regarding the Company available, including any
other documents released by the Company that may contain more
detailed information. Adjusted EBITDA, adjusted EBITDA as a
percentage of sales, working capital as a percentage of sales,
adjusted EBITDA margin, working capital, adjusted net profit,
adjusted profit per share, adjusted gross debt, and net cash/debt
are non-IFRS financial metrics that management uses in its decision
making. CENTOGENE has included these financial metrics to provide
supplemental measures of its performance. The Company believes
these metrics are important and useful to investors because they
eliminate items that have less bearing on the Company’s current and
future operating performance and highlight trends in its core
business that may not otherwise be apparent when relying solely on
IFRS financial measures.
CONTACT
CENTOGENE
Melissa HallCorporate Communications Press@centogene.com
Lennart StreibelInvestor Relations
IR@centogene.com
|
Centogene N.V.Consolidated statements of
comprehensive loss for the years ended December 31, 2023,
2022 and 2021(in EUR k) |
|
|
|
Note |
|
2023 |
|
|
2022 |
|
|
2021 |
|
|
|
|
|
|
|
|
|
|
Revenue |
|
7.2 |
|
48,536 |
|
|
47,473 |
|
|
42,234 |
|
Cost of
sales |
|
|
|
31,287 |
|
|
27,712 |
|
|
28,735 |
|
Gross profit |
|
|
|
17,249 |
|
|
19,761 |
|
|
13,499 |
|
Research
and development expenses |
|
|
|
12,361 |
|
|
17,488 |
|
|
19,297 |
|
General
administrative expenses |
|
|
|
32,588 |
|
|
32,587 |
|
|
43,480 |
|
Selling
expenses |
|
|
|
12,564 |
|
|
9,924 |
|
|
9,326 |
|
Impairment of financial assets |
|
|
|
812 |
|
|
— |
|
|
827 |
|
Gain on
reversal of financial asset impairment |
|
|
|
— |
|
|
432 |
|
|
— |
|
Other
operating income |
|
8.1 |
|
11,848 |
|
|
3,774 |
|
|
2,894 |
|
Other
operating expenses |
|
8.2 |
|
431 |
|
|
741 |
|
|
86 |
|
Operating loss |
|
|
|
(29,659 |
) |
|
(36,773 |
) |
|
(56,623 |
) |
Losses from investments
accounted for by the Equity method |
|
15 |
|
(302 |
) |
|
— |
|
|
— |
|
Gains/(losses) on changes in fair value of warrants |
|
8.3 |
|
(159 |
) |
|
2,574 |
|
|
— |
|
Interest
and similar income |
|
|
|
3,293 |
|
|
512 |
|
|
3 |
|
Interest
and similar expenses |
|
|
|
8,418 |
|
|
4,909 |
|
|
802 |
|
Financial costs, net |
|
8.3 |
|
(5,284 |
) |
|
(1,823 |
) |
|
(799 |
) |
Loss before taxes from continuing operations |
|
|
|
(35,245 |
) |
|
(38,596 |
) |
|
(57,422 |
) |
Income
taxes expenses |
|
10 |
|
287 |
|
|
107 |
|
|
(70 |
) |
Loss for the year from continuing operations |
|
|
|
(35,532 |
) |
|
(38,703 |
) |
|
(57,352 |
) |
Net
income from discontinued operations, net of tax |
|
9 |
|
— |
|
|
6,862 |
|
|
11,106 |
|
Loss for the period |
|
|
|
(35,532 |
) |
|
(31,841 |
) |
|
(46,246 |
) |
Other
comprehensive income/(loss), all attributable to equity holders of
the parent |
|
|
|
(271 |
) |
|
(76 |
) |
|
543 |
|
Total comprehensive loss |
|
|
|
(35,803 |
) |
|
(31,917 |
) |
|
(45,703 |
) |
Attributable to: |
|
|
|
|
|
— |
|
|
— |
|
Equity
holders of the parent |
|
|
|
(35,803 |
) |
|
(31,917 |
) |
|
(45,801 |
) |
Non‑controlling interests from continuing operations |
|
25 |
|
— |
|
|
— |
|
|
98 |
|
Non‑controlling interests from discontinued operations |
|
|
|
— |
|
|
— |
|
|
— |
|
|
|
|
|
(35,803 |
) |
|
(31,917 |
) |
|
(45,703 |
) |
Net loss per share - Basic and diluted from (in
EUR) |
|
|
|
|
|
|
|
|
Continuing operations |
|
11 |
|
(1.27 |
) |
|
(1.45 |
) |
|
(2.53 |
) |
Loss
attributable to parent |
|
11 |
|
(1.27 |
) |
|
(1.19 |
) |
|
(2.04 |
) |
|
|
|
|
|
|
|
|
|
The accompanying notes form an integral part of these consolidated
financial statements |
|
Centogene N.V.Consolidated statements of
financial position as of December 31, 2023 and
2022(in EUR k) |
|
Assets |
|
Note |
|
Dec 31, 2023 |
|
|
Dec 31, 2022 |
|
|
|
|
|
|
|
|
|
|
Non‑current
assets |
|
|
|
|
|
|
|
|
Intangible assets |
|
12 |
|
6,850 |
|
|
7,400 |
|
Property, plant and equipment |
|
13 |
|
5,643 |
|
|
6,808 |
|
Right-of-use assets |
|
14 |
|
13,635 |
|
|
15,351 |
|
Investment in Joint Venture |
|
15 |
|
2,784 |
|
|
— |
|
Derivative assets |
|
23.1 |
|
799 |
|
|
510 |
|
Other assets |
|
17 |
|
3,425 |
|
|
2,911 |
|
|
|
|
|
33,136 |
|
|
32,980 |
|
Current
assets |
|
|
|
|
|
|
|
|
Inventories |
|
16 |
|
2,463 |
|
|
1,819 |
|
Trade receivables and contract assets |
|
17 |
|
19,415 |
|
|
16,548 |
|
Other assets |
|
17 |
|
3,042 |
|
|
5,514 |
|
Cash and cash equivalents |
|
18 |
|
19,099 |
|
|
35,951 |
|
|
|
|
|
44,019 |
|
|
59,832 |
|
|
|
|
|
77,155 |
|
|
92,812 |
|
|
|
|
|
|
|
|
Equity and liabilities |
|
Note |
|
Dec 31, 2023 |
|
Dec 31, 2022 |
|
|
|
|
|
|
|
Equity |
|
|
|
|
|
|
Issued capital |
|
19 |
|
3,478 |
|
|
3,307 |
|
Capital reserve |
|
19 |
|
148,308 |
|
|
145,369 |
|
Accumulated deficit and other reserves |
|
|
|
(177,068 |
) |
|
(141,265 |
) |
Non‑controlling interests |
|
|
|
— |
|
|
— |
|
|
|
|
|
(25,282 |
) |
|
7,411 |
|
Non‑current
liabilities |
|
|
|
|
|
|
Non‑current loans |
|
21.1 |
|
39,880 |
|
|
40,051 |
|
Lease liabilities |
|
21.1 |
|
12,399 |
|
|
13,125 |
|
Deferred tax liabilities |
|
10 |
|
407 |
|
|
35 |
|
Government grants |
|
21.2 |
|
5,701 |
|
|
6,687 |
|
Derivative liabilities |
|
21.2, 23 |
|
242 |
|
|
376 |
|
Warrant liability |
|
21.2, 23 |
|
394 |
|
|
260 |
|
Other liabilities |
|
21.2, 22 |
|
48 |
|
|
202 |
|
|
|
|
|
59,071 |
|
|
60,736 |
|
Current
liabilities |
|
|
|
|
|
|
Government grants |
|
21.2 |
|
984 |
|
|
1,263 |
|
Current loans |
|
21.1 |
|
25,882 |
|
|
4,635 |
|
Lease liabilities |
|
21.1 |
|
2,178 |
|
|
2,311 |
|
Liabilities from income taxes |
|
|
|
87 |
|
|
89 |
|
Trade payables |
|
21.2 |
|
5,628 |
|
|
6,317 |
|
Other liabilities |
|
21.2, 22 |
|
8,607 |
|
|
10,050 |
|
|
|
|
|
43,366 |
|
|
24,665 |
|
|
|
|
|
77,155 |
|
|
92,812 |
|
|
The accompanying notes form an integral part of these consolidated
financial statements |
|
Centogene N.V.Consolidated statements of
cash flows for the years ended December 31, 2023, 2022
and 2021(in EUR k) |
|
|
|
|
|
|
|
|
|
|
|
|
Note |
|
2023 |
|
|
2022 |
|
|
2021 |
|
Operating
activities |
|
|
|
|
|
|
|
|
Loss before taxes from
continuing operations |
|
|
|
(35,245 |
) |
|
(38,596 |
) |
|
(57,422 |
) |
Income before taxes from
discontinued operations |
|
9 |
|
— |
|
|
6,875 |
|
|
11,152 |
|
Loss before taxes |
|
|
|
(35,245 |
) |
|
(31,721 |
) |
|
(46,270 |
) |
Adjustments to
reconcile earnings to cash flow from operating
activities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization (including impairments) and depreciation |
|
12,13,14 |
|
7,610 |
|
|
10,378 |
|
|
19,974 |
|
Government grant depreciation |
|
|
|
(1,265 |
) |
|
— |
|
|
— |
|
Inventory write-off |
|
16 |
|
226 |
|
|
— |
|
|
1,795 |
|
Interest income |
|
8.3 |
|
(209 |
) |
|
— |
|
|
(3 |
) |
Interest expense |
|
8.3 |
|
8,201 |
|
|
4,909 |
|
|
851 |
|
Gain on the disposal of property, plant and equipment |
|
|
|
(56 |
) |
|
(754 |
) |
|
(18 |
) |
Gain on the sales of IP to Joint Venture |
|
8.1 |
|
(7,549 |
) |
|
— |
|
|
— |
|
Expected credit loss allowances on trade receivables and contract
assets |
|
23.2 |
|
761 |
|
|
— |
|
|
827 |
|
Share‑based payment expenses |
|
22 |
|
2,929 |
|
|
(16 |
) |
|
8,035 |
|
Tax Expense |
|
|
|
— |
|
|
(89 |
) |
|
— |
|
Profit or loss from financial instruments FV adjustments |
|
8.3 |
|
(263 |
) |
|
(2,574 |
) |
|
— |
|
Loss from Joint Venture equity method |
|
15 |
|
302 |
|
|
— |
|
|
— |
|
Other non‑cash items |
|
|
|
(34 |
) |
|
(1,430 |
) |
|
(821 |
) |
Net foreign exchange differences |
|
|
|
(2,438 |
) |
|
963 |
|
|
— |
|
Interest received |
|
|
|
209 |
|
|
— |
|
|
— |
|
Changes in operating
assets and liabilities: |
|
|
|
|
|
|
|
|
Inventories |
|
16 |
|
(870 |
) |
|
2,050 |
|
|
5,741 |
|
Trade receivables and contract assets |
|
17 |
|
(3,628 |
) |
|
6,914 |
|
|
4,855 |
|
Other assets |
|
17 |
|
1,858 |
|
|
- |
|
|
1,828 |
|
Trade payables |
|
21.2 |
|
(689 |
) |
|
(4,935 |
) |
|
(20,484 |
) |
Other liabilities |
|
|
|
(1,599 |
) |
|
(10,182 |
) |
|
1,952 |
|
|
|
|
|
|
|
|
|
|
Thereof cash flow (used in)
continuing operating activities |
|
|
|
(31,749 |
) |
|
(35,497 |
) |
|
(42,635 |
) |
Thereof cash flow from
discontinued operating activities |
|
|
|
— |
|
|
9,009 |
|
|
20,897 |
|
Cash flow (used
in)/from operating activities |
|
|
|
(31,749 |
) |
|
(26,488 |
) |
|
(21,739 |
) |
|
|
|
|
|
|
|
|
|
Investing
activities |
|
|
|
|
|
|
|
|
Cash paid for investments in
intangible assets |
|
12 |
|
(2,239 |
) |
|
(1,727 |
) |
|
(2,787 |
) |
Cash paid for investments in
property, plant and equipment |
|
13 |
|
(40 |
) |
|
(367 |
) |
|
(2,915 |
) |
Cash paid for investment in
Joint Venture |
|
15 |
|
(4,973 |
) |
|
— |
|
|
— |
|
Grants received for investment
in property, plant and equipment |
|
21.2 |
|
— |
|
|
506 |
|
|
168 |
|
Cash received from the
disposals of property, plant and equipment |
|
|
|
93 |
|
|
855 |
|
|
171 |
|
Cash received from sale of IP
to Joint Venture |
|
15 |
|
9,436 |
|
|
— |
|
|
— |
|
Interest received |
|
|
|
— |
|
|
— |
|
|
3 |
|
|
|
|
|
|
|
|
|
|
Thereof cash flow from/(used
in) in continuing investing activities |
|
|
|
2,277 |
|
|
(1,553 |
) |
|
(2,494 |
) |
Thereof cash flow from/(used
in) discontinued investing activities |
|
|
|
— |
|
|
820 |
|
|
(2,866 |
) |
Cash flow used in
investing activities |
|
|
|
2,277 |
|
|
(733 |
) |
|
(5,360 |
) |
|
|
|
|
|
|
|
|
|
Financing
activities |
|
|
|
|
|
|
|
|
Cash received from the
issuance of shares |
|
19 |
|
— |
|
|
12,140 |
|
|
— |
|
Cash received from issuance of
warrants |
|
|
|
— |
|
|
2,833 |
|
|
— |
|
Cash paid for acquisition of
non-wholly owned subsidiary |
|
|
|
— |
|
|
(1 |
) |
|
— |
|
Cash received from loans |
|
21, 23.2 |
|
25,500 |
|
|
40,568 |
|
|
1,772 |
|
Cash repayments of loans |
|
21, 23.2 |
|
(3,374 |
) |
|
— |
|
|
(464 |
) |
Cash repayments of lease
liabilities |
|
21, 23.2 |
|
(3,095 |
) |
|
(4,314 |
) |
|
(4,244 |
) |
Interest paid |
|
8.3 |
|
(5,987 |
) |
|
(4,909 |
) |
|
(267 |
) |
|
|
|
|
|
|
|
|
|
Thereof net cash flow
from/(used in) continuing financing activities |
|
|
|
13,044 |
|
|
46,798 |
|
|
(2,403 |
) |
Thereof net cash flow used in
discontinued financing activities |
|
|
|
— |
|
|
(481 |
) |
|
(800 |
) |
Cash flow from
financing activities |
|
|
|
13,044 |
|
|
46,317 |
|
|
(3,203 |
) |
|
|
|
|
|
|
|
|
|
Changes in cash and cash
equivalents |
|
|
|
(16,428 |
) |
|
19,096 |
|
|
(30,302 |
) |
Cash and cash equivalents at
the beginning of the period |
|
|
|
35,951 |
|
|
17,818 |
|
|
48,156 |
|
Effect of movements in
exchange rates on cash held |
|
|
|
(424 |
) |
|
(963 |
) |
|
(36 |
) |
Cash and cash equivalents at
the end of the period |
|
|
|
19,099 |
|
|
35,951 |
|
|
17,818 |
|
|
The accompanying notes form an integral part of these consolidated
financial statements |
Centogene NV (NASDAQ:CNTG)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
Centogene NV (NASDAQ:CNTG)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024